Alembic Aims To Build On Booming US Business

Launches Let US Sales Leap By 61%

With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.

Graph_US_Growth
Alembic Pharma is enjoying strong growth in the US generics market • Source: Shutterstock

Alembic Pharmaceuticals intends to continue building on a strong performance in the US generics sector by lining up more launches and expanding its portfolio beyond its strength in solid oral doses.

In early January, a formulations facility in Karkhadi, India, operated by the firm’s 60/40 Aleor Dermaceuticals skincare joint venture with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business